Harrow Q2 2020 Earnings Report
Key Takeaways
Harrow Health reported its results for the second quarter of 2020, noting that the impact from COVID-19 was substantial for a limited period, but the segments of the economy that are most relevant to their success recovered rapidly and are now at near-normal levels.
The company made great progress during a challenging second quarter.
The impact from COVID-19 was substantial for a limited period, but the segments of the economy that are most relevant to the company's success recovered rapidly and are now at near-normal levels.
The company is seeing trends of record-high revenue days into the third quarter as the economy and healthcare providers continue to make a strong comeback.
The company announced a partnership with EyePoint Pharmaceuticals to market FDA-approved DEXYCU®.